|
An Encouraging Turn in the Study - Report on Cara Therapeutics Inc. - PR Newswire (press release) |
 |
 |
|
NEW YORK, July 31, 2015 /PRNewswire/ -- ACI Association has initiated research coverage on Cara Therapeutics Inc. (NASDAQ:CARA). Select highlights from the internally released reports are being made available to the general public (included below), with access to the entirety of the research available to new members.
Today, membership is open to readers on a complementary basis at the following URL: http://www.aciassociation.com/?c=CARA
Highlights from our CARA Report include:
- Cara Therapeutics announces statistically significant results - On July 23, 2015, Cara Therapeutics, Inc. announced that the topline results from its Phase 2 trial of its lead kappa opioid agonist, CR845, for the treatment of moderate to severe uremic pruritus (UP) were statistically significant.
- The Phase 2 Trial - The Phase 2 Trial conducted by the Company was a double-blind, randomized, placebo-controlled trial devised to evaluate the efficacy of I.V. CR845 compared to placebo in reducing the intensity of itch in dialysis patients over a two-week dosing period. For the trial, Cara Therapeutics enrolled 65 dialysis patients at multiple sites in the United States. According to the Company, the primary endpoint of the Phase 2 trial was the change from baseline of the average worst itching during the second week of treatment, as was recorded on a visual analog scale (VAS).
- Management Views - Derek Chalmers, Ph.D., D.Sc., the CEO and President of Cara Therapeutics said that the results demonstrated the potential of Cara's lead candidate CR845 to address an additional indication of significant unmet need beyond its lead I.V. CR845 program in acute pain. Joseph Stauffer, D.O., M.B.A., the Chief Medical Officer of the Company said that the management was excited by the topline results in uremic pruritus, as they show that I.V. CR845 holds significant clinical potential in what seems as an indication of significant unmet need for dialysis patients. Dr. James Tumlin, Professor, Department of Medicine, University of Tennessee and a Principal Investigator on the trial said that with no approved therapy and the limited efficacy of current options, CR845 provides an opportunity to relieve the pain and discomfort of this persistent clinical problem among ESRD patients.
To find out how this influences our rating on Cara Therapeutics, Inc. read the full report in its entirety here: http://www.aciassociation.com/?c=CARA
--
About ACI Association:
Active Charter Investors Association ("ACI Association") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ACI Association has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
ACI Association has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the CFA® have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the CFA® (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.
NO WARRANTY
ACI Association, the Author, the Reviewer and the CFA® (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ACI Association nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.aciassociation.com/.
RESTRICTIONS
ACI Association is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia. Do not send email to robottrap (at) aciassociation.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE www.aciassociation.com
|
|
An Encouraging Turn in the Study - Report on Cara Therapeutics Inc. - MarketWatch |
|
|
|
NEW YORK, July 31, 2015 /PRNewswire via COMTEX/ -- NEW YORK, July 31, 2015 /PRNewswire/ --
ACI Association has initiated research coverage on Cara Therapeutics Inc.
CARA, +9.28%
Select highlights from the internally released reports are being made available to the general public (included below), with access to the entirety of the research available to new members.
Today, membership is open to readers on a complementary basis at the following URL: http://www.aciassociation.com/?c=CARA
Highlights from our CARA Report include:
- C ara Therapeutics announces statistically significant results - On July 23, 2015, Cara Therapeutics, Inc. announced that the topline results from its Phase 2 trial of its lead kappa opioid agonist, CR845, for the treatment of moderate to severe uremic pruritus (UP) were statistically significant.
- The Phase 2 Trial - The Phase 2 Trial conducted by the Company was a double-blind, randomized, placebo-controlled trial devised to evaluate the efficacy of I.V. CR845 compared to placebo in reducing the intensity of itch in dialysis patients over a two-week dosing period. For the trial, Cara Therapeutics enrolled 65 dialysis patients at multiple sites in the United States. According to the Company, the primary endpoint of the Phase 2 trial was the change from baseline of the average worst itching during the second week of treatment, as was recorded on a visual analog scale (VAS).
- Management Views - Derek Chalmers, Ph.D., D.Sc., the CEO and President of Cara Therapeutics said that the results demonstrated the potential of Cara's lead candidate CR845 to address an additional indication of significant unmet need beyond its lead I.V. CR845 program in acute pain. Joseph Stauffer, D.O., M.B.A., the Chief Medical Officer of the Company said that the management was excited by the topline results in uremic pruritus, as they show that I.V. CR845 holds significant clinical potential in what seems as an indication of significant unmet need for dialysis patients. Dr. James Tumlin, Professor, Department of Medicine, University of Tennessee and a Principal Investigator on the trial said that with no approved therapy and the limited efficacy of current options, CR845 provides an opportunity to relieve the pain and discomfort of this persistent clinical problem among ESRD patients.
To find out how this influences our rating on Cara Therapeutics, Inc. read the full report in its entirety here: http://www.aciassociation.com/?c=CARA
About ACI Association:
Active Charter Investors Association ("ACI Association") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ACI Association has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
ACI Association has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the CFA® have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the CFA® (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.
NO WARRANTY
ACI Association, the Author, the Reviewer and the CFA® (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ACI Association nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.aciassociation.com/.
RESTRICTIONS
ACI Association is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia. Do not send email to robottrap (at) aciassociation.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE www.aciassociation.com
Copyright (C) 2015 PR Newswire. All rights reserved
|
|
|
Fresenius Medical Care AG Co. Price Target Raised to $40.00 (FMS) - Dakota Financial News |
|
|
|
 Equities research analysts at RBC Capital boosted their target price on shares of Fresenius Medical Care AG & Co. (NYSE:FMS) from $35.00 to $40.00 in a report released on Friday, Marketbeat reports. The firm presently has a “sector perform” rating on the stock. RBC Capital’s price target would suggest a potential downside of 2.58% from the stock’s previous close.
Fresenius Medical Care AG & Co. (NYSE:FMS) opened at 41.04 on Friday. The firm has a 50-day moving average price of $42.60 and a 200 day moving average price of $41.17. The firm has a market capitalization of $24.94 billion and a price-to-earnings ratio of 23.74. Fresenius Medical Care AG & Co. has a 12 month low of $32.40 and a 12 month high of $44.34.
Fresenius Medical Care AG & Co. (NYSE:FMS) last issued its quarterly earnings data on Thursday, July 30th. The company reported $0.40 earnings per share (EPS) for the quarter, missing the Thomson Reuters consensus estimate of $0.43 by $0.03. The firm earned $4.20 billion during the quarter, compared to the consensus estimate of $4.13 billion. The company’s quarterly revenue was up 15.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.42 earnings per share. On average, equities analysts forecast that Fresenius Medical Care AG & Co. will post $1.76 EPS for the current year.
Separately, Commerzbank AG downgraded shares of Fresenius Medical Care AG & Co. to a “hold” rating in a research report on Friday, May 29th. Seven equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $37.78.
Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) is a kidney dialysis company. The Company provides dialysis care services related to the dialysis treatment a patient receives with end-stage renal disease (ESRD), as well as other health care services. FMC AG & CO. KGAA also provides dialysis products for the treatment of ESRD, which includes manufacturing and distributing products, such as hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals and systems for water treatment. The Company’s health care services, referred to as care coordination services, include pharmacy services, vascular, cardiovascular and endovascular specialty services, non-dialysis laboratory testing services, physician services, hospitalist and intensivist services, health plan services and urgent care services. The Company also offers a range of dialysis drugs.
Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.
|
|
Expanded Souris dialysis clinic open - The Guardian |
|
|
|
SOURIS - Trying to fight his way through snow and ice to get to Charlottetown last winter drained dialysis patient Tom Eldershaw.
“It’s a long haul and even worse when you have to battle the weather,” he said. “It pretty well zaps your entire energy.”
It’s a two hour drive there and back from the eastern port town to the capital city even longer in winter driving conditions.
Eldershaw had to make the drive three times a week just to stay alive.
Add on the three hour dialysis treatment once you get to the Queen Elizabeth Hospital in Charlottetown and that pretty well eats up the day.
So Eldershaw and fellow kidney patient Jim Campbell were beaming Thursday after Health Minister Doug Currie held an open house for the newly expanded dialysis unit at the Souris hospital.
The minister unveiled the $300,000 renovation which provides a modern and spacious treatment area and a major upgrade to the water filtration system.
“We are now providing a higher standard of care in Souris which is very important to the patients who require this life sustaining treatment,” he said.
RELATED: Souris dialysis clinic closes over water filtration issues
Three years ago, Currie was the helm when Health P.E.I. recommended closing the unit entirely and relocating patients to Charlottetown for treatment.
That stirred up a hornet’s nest.
The threat of rural decay and lost services created such a backlash in eastern P.E.I. that hundreds of residents filled public meetings and led protests at the P.E.I. legislature.
“There was a direction from Health P.E.I. about capacity and there were lots of competing demands on the health system at that time,’’ Currie said during an interview. “It wasn’t a case of government changing its’ mind….the reality is the intense growth and demand for dialysis needs which puts pressure on the health system and that’s why we’ve expanded here.”
The expansion provides more individual space and privacy for patients and now allows up to 12 patients per week to receive treatment rather than 10.
One of the most vocal patients against any reduction of services in Souris was Nathan Bushey, who ran for the NDP in the last election.
He helped submit a brief to government in May 2012 advising of the health ramifications to dialysis patients having to travel more than 15 minutes for treatment.
“I think public pressure did it and the democratic process worked,’’ he said during the open house. “The government overturned their original decision to close because of the public outcry.”
“We’ve already seen the positive impact this expansion has had on the quality of dialysis care we provide and on the work-life of our staff,’’ said Cheryl Banks, director of provincial renal program.
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Twitter.com/PEIGuardian
|
|
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
